

RESEARCH ARTICLE

The cellular and molecular etiology of the craniofacial defects in the avian ciliopathic mutant *talpid²*

Ching-Fang Chang^{1,2}, Elizabeth N. Schock^{1,2}, Elizabeth A. O'Hare^{3,*}, Jerry Dodgson⁴, Hans H. Cheng⁵, William M. Muir⁶, Richard E. Edelmann⁷, Mary E. Delany³ and Samantha A. Brugmann^{1,2,†}

ABSTRACT

talpid² is an avian autosomal recessive mutant with a myriad of congenital malformations, including polydactyly and facial clefting. Although phenotypically similar to *talpid³*, *talpid²* has a distinct facial phenotype and an unknown cellular, molecular and genetic basis. We set out to determine the etiology of the craniofacial phenotype of this mutant. We confirmed that primary cilia were disrupted in *talpid²* mutants. Molecularly, we found disruptions in Hedgehog signaling. Post-translational processing of GLI2 and GLI3 was aberrant in the developing facial prominences. Although both GLI2 and GLI3 processing were disrupted in *talpid²* mutants, only GLI3 activator levels were significantly altered in the nucleus. Through additional fine mapping and whole-genome sequencing, we determined that the *talpid²* phenotype was linked to a 1.4 Mb region on GGA1q that contained the gene encoding the ciliary protein C2CD3. We cloned the avian ortholog of *C2CD3* and found its expression was ubiquitous, but most robust in the developing limbs and facial prominences. Furthermore, we found that C2CD3 is localized proximal to the ciliary axoneme and is important for docking the mother centriole to the ciliary vesicle and cell membrane. Finally, we identified a 19 bp deletion in *talpid²* *C2CD3* that produces a premature stop codon, and thus a truncated protein, as the likely causal allele for the phenotype. Together, these data provide insight into the cellular, molecular and genetic etiology of the *talpid²* phenotype. Our data suggest that, although the *talpid²* and *talpid³* mutations affect a common ciliogenesis pathway, they are caused by mutations in different ciliary proteins that result in differences in craniofacial phenotype.

KEY WORDS: Primary cilia, Craniofacial, *talpid²*, Gli processing, Hedgehog signaling, Ciliopathies, Chicken

INTRODUCTION

The chick is a classic embryological system that has been meticulously documented and described (Hamburger and Hamilton, 1951). Several institutions have bred and maintained

mutant avian lines that have lent a significant amount of insight into numerous developmental processes (Robb et al., 2011). Some of the most well-studied avian genetic developmental mutants have been the talpids (*talpid*, *talpid²* and *talpid³*): three independently discovered, naturally occurring, autosomal recessive, lethal mutants characterized by pre-axial polydactyly, craniofacial anomalies and a host of other developmental defects (Abbott et al., 1959; Ede and Kelly, 1964a,b; MacCabe and Abbott, 1974). Although *talpid* became extinct, the study of the genetic and molecular etiology of the *talpid²* and *talpid³* phenotypes continues.

talpid² and *talpid³* have similar limb phenotypes, yet the craniofacial phenotypes are distinct. *talpid³* has severe hypotelorism, a hypoplastic frontonasal mass superior to the eyes, medially fused nasal placodes, a narrow and peg-like lower beak, and an oral cavity that is divided in two by the maxillary prominences fusing across the midline (Abbott et al., 1959, 1960; Ede and Kelly, 1964a; Hinchliffe and Ede, 1968; Buxton et al., 2004). By contrast, the *talpid²* facial phenotype is characterized by a short yet wide frontonasal prominence, bilateral clefting between the frontonasal and lateral nasal prominence and hypoglossia/aglossia (Schneider et al., 1999; Brugmann et al., 2010). Molecularly, the *talpid³* mutant has been more extensively studied and attributed to disruptions in Sonic Hedgehog (SHH) signaling (Buxton et al., 2004; Davey et al., 2006, 2007). Whereas the defect in SHH signaling was clear, understanding the molecular mechanism for the phenotype was confounded by the fact that the facial phenotype was indicative of a loss of SHH function, but the limb phenotype was indicative of a gain of SHH function (Buxton et al., 2004; Davey et al., 2006, 2007). A deeper understanding of the molecular etiology of the mutant was gained when the causal genetic element for *talpid³* was identified and characterized as a protein (now called TALPID3 after the mutant itself) that localizes to the basal body of the primary cilia (Yin et al., 2009).

Primary cilia are ubiquitous organelles that serve as a cellular hub for the transduction of numerous signaling pathways. Most notably, cilia have been identified as the location for post-translational processing of GLI proteins (Goetz and Anderson, 2010). GLI proteins are transcription factors that regulate a number of cellular processes (e.g. proliferation, specification and differentiation). Full-length GLI (GLIFL) can be processed via phosphorylation into the activator isoform (GLIA) or cleaved into the repressor isoform (GLIR) (Liu et al., 2005). Inhibition of GLI processing prevents production of GLIA and GLIR isoforms (Haycraft et al., 2005). Thus, an essential role of primary cilia is to establish the ratio of GLIA to GLIR proteins, which in turn controls transcription of SHH target genes.

Our earlier studies regarding the molecular mechanism of *talpid²* suggested defects in primary cilia (Brugmann et al., 2010); however, these studies did not address the extent of ciliary dysfunction, molecular consequences of aberrant cilia or the genetic cause of the mutation. Studies from other groups have suggested that the polydactylous phenotype of *talpid²* was

¹Division of Plastic Surgery, Department of Surgery, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA. ²Division of Developmental Biology, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA. ³College of Agricultural and Environmental Sciences, Department of Animal Science, University of California Davis, Davis, CA 95616, USA. ⁴Microbiology and Molecular Genetics, Michigan State University, East Lansing, MI 48824, USA. ⁵USDA Avian Disease and Oncology Laboratory, East Lansing, MI 48823, USA.

⁶Department of Animal Sciences, Purdue University, West Lafayette, IN 47907, USA. ⁷Center for Advanced Microscopy and Imaging, Miami University, Oxford, OH 45056, USA.

*Present address: School of Medicine, Division of Endocrinology, Diabetes, and Nutrition, University of Maryland, Baltimore, MD 21201, USA.

†Author for correspondence (samantha.brugmann@cchmc.org)

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/3.0>), which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed.

attributable to constitutive activation of SHH signaling, in which activation of the SHH pathway occurs in the absence of a SHH ligand (Caruccio et al., 1999). The limb phenotype in the *talpid²* mutant has been attributed to defects in GLI processing (Caruccio et al., 1999), but an in-depth analysis of GLI protein expression in the facial prominences has not been explored.

No direct comparison or complementation analysis of *talpid²* and *talpid³* mutants has been undertaken. The similar phenotypes of the mutants raised the possibilities that the causative genetic elements for these mutants were: (1) alleles of the same gene with different grades of expression (Ede and Kelly, 1964b); (2) separate genetic insults within the same pathway; or (3) completely separate defects. Herein, we explore the cellular and molecular basis for the *talpid²* craniofacial mutation, comparing our findings with those in the *talpid²* limb and in *talpid³*. Furthermore, we use whole-genome sequencing of inbred *talpid²* lines to identify the causative locus for the *talpid²* mutation and confirm that it is distinct from the *talpid³* mutation.

RESULTS

talpid² embryos have craniofacial defects

Although craniofacial defects have been previously reported in *talpid²* embryos (Abbott et al., 1959; Yee and Abbott, 1978; Caruccio et al., 1999; Schneider et al., 1999; Brugmann et al., 2010), an in-depth analysis of the development of facial prominences has not been reported. We examined control and *talpid²* embryos and analyzed the growth of the frontonasal, maxillary and mandibular prominences (Fig. 1). *talpid²* embryos displayed bilateral clefting between the frontonasal, lateral nasal and maxillary prominences (Fig. 1A,B). The frontonasal prominence was significantly shorter and wider in *talpid²* embryos relative to controls (Fig. 1A,B,G). Growth of the maxillary prominence was also disrupted. The maxillary prominences fuse to form the secondary palate. In avians, part of the secondary palate remains patent (Lillie, 1908) (Fig. 1C). In contrast to control embryos, the extent of patency was significantly increased in *talpid²* embryos (Fig. 1C,D,G). We also measured inner intercanthal distance and the width of the lateral nasal prominence. Neither of those measurements showed significant variation between control and *talpid²* embryos (data not shown). Thus, we conclude that the predominant cause of clefting in the *talpid²* embryos is the aberrant growth of the frontonasal and maxillary prominences. Finally, we analyzed the growth of the mandibular prominence. The mandibular prominences of *talpid²* embryos fail to fuse completely (Fig. 1E,F). In addition, a large percentage of *talpid²* embryos (10/12; 83%) exhibit hypoglossia/aglossia (Fig. 1E,F). These data confirm that the growth and development of the facial prominences are significantly disrupted in *talpid²* embryos.

Primary cilia are disrupted throughout the *talpid²* embryo

The *talpid³* phenotype had previously been shown to be a product of disrupted primary cilia (Yin et al., 2009). Our previous work identified disrupted cilia in *talpid²* mutants (Brugmann et al., 2010). We confirmed this finding by performing immunostaining with glutamylated-tubulin on facial mesenchyme (Fig. 2A,B). Glutamylated-tubulin staining in control avian embryos is localized to the ciliary axoneme (Fig. 2A), whereas staining in the *talpid²* mesenchyme is diffuse and unorganized (Fig. 2B). We also examined γ -tubulin staining in the centrosome (Fig. 2C,D). We found abundant, punctate γ -tubulin staining in the mesenchyme of control embryos (Fig. 2C). Although we were able to detect γ -tubulin in *talpid²* embryos (Fig. 2D), some staining was diffuse and not as punctate as in control embryos (Fig. 2D). To further characterize ciliary extension in the




Fig. 1. Growth and development of the facial prominences is disrupted in *talpid²* mutants. Day 7 control ($n=10$) and *talpid²* ($n=4$) embryos. (A,B) Frontal views of facial prominences; frontonasal (fnp), maxillary (mxp) and mandibular prominences (mnp). Bilateral clefting in *talpid²* embryos (white arrows in B). (C,D) Palatal views show increased patency of both the primary and secondary palate of *talpid²* embryos (dotted yellow line). (E,F) Dorsal view of the mnp. The mnp of *talpid²* embryos is clefted (white arrow in F) and exhibits hypoglossia (dotted yellow line). (G) Quantitative analysis of fnp and mxp growth. For fnp length, * $P<0.02$; for fnp width, * $P<0.02$; for infranasal width, * $P<0.04$; for patent palate, * $P<0.02$. t, tongue. Data are mean \pm s.e.m. Scale bars: 1 mm (A-F).

talpid² mutants, we performed scanning electron microscopy in the forebrain (Fig. 2E,F). We found numerous ciliary extensions within a ciliary pocket (Fig. 2E) in control embryos. In *talpid²* embryos, however, the majority of cells did not extend a cilium (Fig. 2F). Finally, we isolated and cultured chicken embryonic fibroblasts (CEFs) from both control and *talpid²* embryos and quantified the percentage of cells extending a cilium. Sixty-four percent of control CEFs extended a glutamylated-tubulin-positive extension adjacent to a punctate domain of γ -tubulin staining (Fig. 2G,I). By contrast, only 32% *talpid²* CEFs extended a glutamylated-tubulin-positive extension adjacent to a punctate domain of γ -tubulin staining (Fig. 2H,I). These results, in conjunction with our previous findings, strongly suggest that the *talpid²* phenotype, like the *talpid³* phenotype, is caused by a ciliary defect.

SHH expression and activity are affected in the developing face and brain of *talpid²* embryos

Previous studies have reported aberrant *SHH* expression in *talpid²* embryos (Caruccio et al., 1999; Schneider et al., 1999; Agarwala et al., 2005). As ciliary defects have been known to affect various tissues and developmental domains differently, and because previous reports suggest a gain of SHH function in the limb with a loss of SHH function in the face of *talpid³* (Buxton et al., 2004; Davey et al., 2006,




Fig. 2. Primary cilia are disrupted in *talpid2* mutants. (A–D) Immunostaining for ciliary markers on facial sections. (A,B) Anti-glutamylated-tubulin in facial mesenchyme. Red arrows mark axoneme. (C,D) Anti- γ -tubulin in facial mesenchyme. Red arrows mark centriole. (E,F) Scanning electron microscopy of the ventricular surface of the neuroectoderm. Blue lines outline cells; red arrow indicates axoneme; yellow asterisks mark ciliary pockets. (G,H) Double glutamylated- and γ -tubulin immunostaining in CEFs. (I) Quantification of control ($n=686$) and *talpid2* ($n=522$) CEFs extending primary cilia; * $P<0.005$. Data are mean \pm s.e.m. Scale bars: 10 μ m in A–D; 1 μ m in E,F; 20 μ m in G,H.

2007), we examined *SHH* expression and pathway activity in both the developing facial prominences and the developing brain. Quantitative RT-PCR (qRT-PCR) of individual facial prominences demonstrated that levels of *SHH* ligand expression varied in a prominence-specific manner. *SHH* expression was increased in both frontonasal and maxillary prominences; however, there was a slight decrease in expression in the mandibular prominence (Fig. 3A). These results were confirmed with *in situ* hybridization for *SHH* in HH25 control and *talpid2* embryos (Fig. 3B). An increase in *SHH* ligand typically results in increased activity of the pathway, as marked by increased *PATCHED* (*PTC*) transcription. Despite increased *SHH* ligand expression, *PTC* expression was significantly reduced in the frontonasal prominence (Fig. 3C). Conversely, *PTC* expression was not significantly altered in either the maxillary or mandibular prominences (Fig. 3C). Variation in *PTC* expression was confirmed with *in situ* hybridization (Fig. 3D). Finally, RNA-seq was performed on individual facial prominences of both control and *talpid2* embryos (Fig. 3E). These data support both qRT-PCR and *in situ* data suggesting that, although *SHH* ligand expression is increased in the

frontonasal and maxillary prominences, pathway activity (as determined by *PTC* expression) is not. These data suggest *SHH* expression is altered in a prominence-specific manner and that ligand expression does not necessarily correlate with canonical *SHH* pathway activity in *talpid2* embryos.

The developing brain strongly influences the developing face (Marcucio et al., 2005; Young et al., 2010; Chong et al., 2012). There are several *SHH* signaling centers in the brain that can influence growth of the craniofacial complex, including the *SHH* domain in the ventral neural tube, forebrain and the zona limitans intrathalamica (ZLI). To determine whether centers of *SHH* activity were disrupted in the brain of *talpid2* embryos, we examined the expression of *SHH* at various stages of development. At HH10, the *SHH* domain in the ventral floor plate was evident in both control and *talpid2* embryos (Fig. 3F,G). At HH20, however, *SHH* expression in both the forebrain and ZLI was significantly reduced (Fig. 3H–K). Thus, although initially established correctly, later *SHH* signaling domains are reduced in the developing brain of *talpid2* embryos.

Post-translational processing of GLI2 is disrupted in the *talpid2* mutant

Functional primary cilia are required for the proper processing of full-length GLI proteins (GLIFL) into either a full-length activator or a cleaved repressor (Haycraft et al., 2005; Liu et al., 2005; May et al., 2005; Humke et al., 2010; Wen et al., 2010). To determine whether the *talpid2* craniofacial phenotype could be attributed to aberrant post-translational processing of the GLI transcription factors, we performed western blot analyses on individual facial prominences. We began our analysis with GLI2 because it functions as the primary activator of the *SHH* pathway (Ding et al., 1998; Motoyama et al., 1998; Park et al., 2000; Bai et al., 2002), and the limb phenotype in *talpid2* embryos is highly suggestive of a gain of *SHH* phenotype. Using an antibody that recognizes both full-length (GLI2-185) and cleaved isoforms (GLI2-78) of GLI2, we found significant disruptions in both the developing facial prominences and limbs (Fig. 4). Relative to control, there was a significant and consistent increase in the levels of GLI2-185 in all *talpid2* facial prominences and limb buds (Fig. 4A). Although GLI2 predominantly functions as a full-length isoform (Pan et al., 2006), we were able to detect an equivalent amount of the cleaved isoform in both control and *talpid2* tissue (Fig. 4A). The ratio of full-length versus cleaved activity is used as a measure of net *SHH* pathway activity (Huangfu and Anderson, 2005). The increase in level of GLI2-185 in *talpid2* mutants resulted in an increased ratio of GLI2-185 to GLI2-78, as quantified by densitometry (Fig. 4B).

To test whether the increased levels of GLI2-185 detected via whole-lysate western blot correlate with increased levels in the nuclear GLI2A in *talpid2* mutants, we performed nuclear fractionation analysis (Fig. 4C). Although we detected increased GLI2-185 in all prominences of the *talpid2* mutant (Fig. 4A,B), our nuclear fractionation result indicated that the levels of nuclear GLI2A were equivalent within control and *talpid2* mutants (Fig. 4C; supplementary material Table S1). Furthermore, we did not note any significant change in the amount of cleaved nuclear GLI2R in *talpid2* mutants (Fig. 4C; supplementary material Table S1). Taken together, our experiments indicate that, although full-length GLI2 processing is impaired in *talpid2* mutants, nuclear levels of GLI2A and GLI2R are not altered.

To function properly, GLI proteins require post-translational modifications, including phosphorylation (Pan et al., 2009; Canetti et al., 2010; Cox et al., 2010; Hui and Angers, 2011). In




Fig. 3. *SHH* signaling is disrupted in the developing face and brain of *talpid2* mutants.

(A) qRT-PCR for *SHH* in frontonasal (FNP), maxillary (MXP) and mandibular (MNP) prominences in control and *talpid2* embryos; * $P < 0.05$. Data are mean \pm s.e.m. (B) *In situ* hybridization for *SHH* in control (n=7) and *talpid2* (n=3) HH25 embryos. (C) qRT-PCR for *PTC*; * $P < 0.03$. Data are mean \pm s.e.m. (D) *In situ* hybridization for *PTC* in control (n=7) and *talpid2* (n=3) HH25 embryos. (E) RNA-seq results for *SHH*, *PTC*, *GLI2* and *GLI3* expression. (F-K) *In situ* hybridization for *SHH* in control and *talpid2* embryos. (F,G) Dorsal view of control (n=11) and *talpid2* (n=9) HH10 embryos. (H-K) Frontal and lateral views of control (n=8) and *talpid2* (n=4) HH20 embryos. Dotted black lines in I,K represent the size of the expression domain in the control embryo (H,J). ZLI, zona limitans intrathalamica. Scale bars: 250 μ m in B,D; 600 μ m in F,G; 100 μ m in H,I; 200 μ m in J,K.

light of our results showing an accumulation of *talpid2* full-length GLI2 with higher mobility than control full-length GLI2 (Fig. 4A) and multiple bands being detected in our nuclear fractionation (Fig. 4C), we tested the hypothesis that improper phosphorylation accounted for the changes in the mobility of GLI2-185 between control and *talpid2*. Phosphatase treatment did not alter mobility of control GLI2-185 to that of *talpid2* GLI2-185 (supplementary material Fig. S1A), suggesting that aberrant phosphorylation is not the cause of increased mobility of *talpid2* full-length GLI2. Regardless of increased mobility of *talpid2* GLI2-185, the mobility and overall amount of *talpid2* GLI2A protein in the nucleus was unchanged relative to control embryos and thus was determined not to be a possible cause for the *talpid2* phenotype.

Post-translational processing of GLI3 is disrupted and GLI3 activator is increased in *talpid2* mutants

We next examined the levels of GLI3 between control and *talpid2* facial prominences (Fig. 5A). Similar to what we observed with

GLI2, we found an increase in the levels of full-length GLI3 (GLI3-190) in *talpid2* facial prominences and limb buds (Fig. 5A). Contrary to what we observed with the cleaved isoform of GLI2, levels of the cleaved GLI3 isoform (GLI3-83) were reduced in the *talpid2* facial prominences relative to controls (Fig. 5A). Quantification of gel images by densitometry indicated that the ratio of GLI3-190 to GLI3-83 was also increased in *talpid2* (Fig. 5B). Thus, our data suggest that in *talpid2*, GLI3 processing is also disrupted, resulting in an accumulation of GLI3-190 at the expense of GLI3-83.

Similar to GLI2, full-length GLI3 can be degraded in the cytoplasm or enter the nucleus as a full-length activator (GLI3A) or cleaved repressor (GLI3R). Contrary to GLI2, GLI3 acts as the predominant repressor of the SHH pathway (Vortkamp et al., 1992; Hui and Joyner, 1993; Biesecker, 1997; Persson et al., 2002). Nuclear fractionation revealed that increased levels of whole lysate GLI3-190 correlated with a robust increase of nuclear GLI3A in *talpid2* mutants (Fig. 5C; supplementary material Table S1).




Fig. 4. Post-translational processing of GLI2 is disrupted in *talpid2* mutants. (A) Western blot analysis for GLI2 in HH 25 facial prominences and limbs. Both full-length GLI2 protein (GLI2-185) and cleaved GLI2 (GLI2-78) are present. Gel mobility of GLI2-185 is higher in *talpid2* (compare black and white asterisks). (B) Ratio of GLI2-185 to GLI2-78 is increased in *talpid2*. * $P < 0.05$. Data are mean \pm s.e.m. (C) Nuclear fractionation detects both GLI2 activator (GLI2A) and GLI2 repressor (GLI2R). LAMIN and GAPDH expression mark the nuclear (N) and cytosolic (C) compartment. T, total protein.

Furthermore, although GLI3-83 levels appeared slightly decreased via whole lysate examination, nuclear fractionation suggests that the total levels of GLI3R in the nucleus are equivalent between the control and *talpid2* embryos (Fig. 5C). Detection of increased nuclear GLI3A supports a hypothesis that increase of GLI3 activator activity is the cause of the *talpid2* facial phenotypes.

To determine the cause of aberrant GLI-190 production, we assessed the phosphorylation status of GLI3-190 in control and *talpid2* embryos using phosphatase treatment (supplementary material Fig. S1B). We did not observe differential gel mobility between control and *talpid2* GLI3-190. Although the amount of GLI3-190 was increased in *talpid2*, we observed similar shifts in mobility. These results indicate that aberrant phosphorylation is not the cause of increased full-length, nuclear GLI3A in *talpid2* mutants.

Genetic mapping and identification of the *talpid2* locus

The *talpid3* phenotype was linked to a ciliary gene encoded on chromosome 5 (GGA5) (Yin et al., 2009). Using a 60K SNP array, we previously identified five candidate chromosome locations (two on GGA1q, two on GGA10q and one on GGA15), none of which mapped to the *talpid3* locus (Robb et al., 2011). Variation between the mutant *talpid2.003* line and the congenic UCD003 control line was examined by whole-




Fig. 5. Post-translational processing of GLI3FL is disrupted in *talpid2*.

(A) Western blot analysis for GLI3 in HH 25 facial prominences and limbs. Both full-length GLI3 protein (GLI3-190) and cleaved GLI3 (GLI3-83) are present. (B) Ratio of GLI3-190 to GLI3-83 is increased in *talpid2*. * $P < 0.05$. (C) Nuclear fractionation detects both GLI3 activator (GLI3A) and GLI3 repressor (GLI3R). LAMIN and GAPDH expression mark the nuclear (N) and cytosolic (C) compartment. T, total protein.

genome sequencing, and candidate genes and alleles were examined at all five intervals (data not shown; supplementary material Tables S2 and S3). These data indicated that the telomeric region of GGA1q (193.7 Mb to 195.2 Mb) exhibited at least a threefold higher ratio of *talpid2*-specific SNPs over any other interval (supplementary material Table S4), suggesting that this interval contained fixed, *talpid2*-specific polymorphisms derived from the original mutant line. Analysis of this interval suggested three potential candidate genes with variations that had potential to impair gene function: *C2CD3* (C2 calcium-dependent domain containing 3), *NUP98* (nucleoporin, 98 kDa) and *NEU3* (neuraminidase 3). We subsequently resequenced all three candidates from both control and mutant samples, and did not find any likely causal polymorphisms, significant changes in transcript size or changes in level of expression in *NUP98* and *NEU3* (data not shown). As demonstrated by our cDNA cloning and sequencing, the chicken ortholog of *C2CD3* produces a 7496 bp transcript with 34 exons (Fig. 6A; supplementary material Fig. S2). Whole-genome sequencing, cDNA sequencing and resequencing of the *talpid2.003* line confirmed one insertion, one deletion and nine missense differences within the *C2CD3* open reading frame between control and *talpid2* genomes (supplementary material Table S5). The majority of the missense variants were likely to be tolerated and were located in




Fig. 6. C2CD3 is the candidate gene for the *talpid2* mutation. (A) Chicken *C2CD3*. A 19 bp deletion was identified within exon 32 of *talpid2*. (B) RT-PCR analysis of *C2CD3* in control, *talpid2* and heterozygous embryos. (C) RT-PCR for *C2CD3* in whole embryos. (D) RT-PCR for *C2CD3* in various domains of HH25 embryos ($n=3$). (E–F') *In situ* hybridization for *C2CD3*. (G) Quantification of CEFs extending cilia after transfection with a control-MO ($n=342$), C2CD3-MO1 ($n=559$), C2CD3-MO2 ($n=551$) or C2CD3-MO1+C2CD3-MO2 ($n=573$); * $P<0.05$, ** $P<0.001$, *** $P<0.0001$. Data are mean \pm s.e.m. (H) Immunofluorescence marking glutamylated-tubulin (arrow) and γ -tubulin (arrowhead) on non-transfected CEFs. (I) Glutamylated-tubulin expression is lost on CEFs transfected with C2CD3-MO1. (J,K) Double immunofluorescence marking glutamylated-tubulin (green) and FLAG (red) on CEFs transfected with p3xFLAG-C2CD3^{Ctrl} (J) or p3xFLAG-C2CD3^{ta2} (K). (L) Western blot analysis of CEFs transfected with p3xFLAG-C2CD3^{Ctrl} and p3xFLAG-C2CD3^{ta2}. Scale bars: 500 μ m in E–F'; 20 μ m in H,I; 10 μ m in J,K.

regions of low complexity (according to protein modeling) with weak evolutionary conservation (data not shown); they were thus not likely to be causative. Moreover, subsequent resequencing of *talpid2* alleles in a commercial background line (rather than being congenic on UCD003, as *talpid2.003* is) eliminated most of the missense mutations as potential causal alleles. The top candidate for the causal mutation was a 19 bp deletion in the 3' end of exon 32 (Fig. 6A) that produces a premature stop codon leading to the deletion of amino acids 2210–2330. PCR analysis supported our sequencing results and detected the 19 bp deletion in *talpid2* mutants (Fig. 6B).

We next examined the temporal and spatial expression of chicken *C2CD3* in control and *talpid2* embryos. Temporally, we found *C2CD3* was robustly expressed throughout craniofacial development (Fig. 6C). To examine spatial expression, we isolated developing face, brain, limb and body from HH25 embryos (Fig. 6D). *C2CD3* was ubiquitously expressed throughout all dissected domains of

control and *talpid2* embryos. Furthermore, we visualized *C2CD3* expression via *in situ* hybridization. Whereas we did not detect any expression with the sense probe (Fig. 6E,F), low levels of ubiquitous expression and higher levels of localized expression in the branchial arches and limbs were detected in both control and *talpid2* embryos (Fig. 6E',F'; supplementary material Fig. S3). This expression pattern is consistent with *C2CD3* expression in murine embryos (Hoover et al., 2008) and consistent with the *talpid2* craniofacial and limb phenotype.

Next, to confirm that C2CD3 plays a role in ciliogenesis, we generated control and two distinct C2CD3-specific morpholinos. Control CEFs were transfected with a control morpholino, or with one or both C2CD3 morpholinos (Fig. 6G). Similar to non-transfected control CEFs (Fig. 2I), ~63% of CEFs transfected with control MO extended a primary cilium (Fig. 6G). After transfection with C2CD3-MO1, C2CD3-MO2 or C2CD3-MO1 plus C2CD3-MO2, the number of CEFs extending cilia was significantly reduced (Fig. 6G). For example, the ciliary basal body and axoneme were clearly present in cells not transfected with C2CD3-MO; however, in the presence of C2CD3-MO, axoneme extension was absent (Fig. 6H,I). Taken together, these experiments suggest that *C2CD3* contains the causal allele for the *talpid2* mutant, that *C2CD3* is expressed in areas correlating with the *talpid2* phenotype and that MO-induced reduction of C2CD3 protein negatively affects ciliary extension.

C2CD3 is hypothesized to localize to either the proximal axoneme (transition zone) (Zhang and Aravind, 2012) or to the distal centriolar region (transition fibers) (Balestra et al., 2013; Ye et al., 2014). To determine where C2CD3 localized within avian cells, we transfected CEFs with FLAG-tagged control *C2CD3* (*C2CD3*^{Ctrl}). We detected FLAG-C2CD3^{Ctrl} adjacent to, but not overlapping with, the ciliary axoneme (Fig. 6J). These results support previous findings in humans and mice suggesting that C2CD3 localizes to the distal aspect of the centrioles within the transition fibers (Balestra et al., 2013; Ye et al., 2014). We next tested whether the 19 bp deletion in *talpid2* *C2CD3* affected the cellular localization of this protein. FLAG-C2CD3^{ta2} was detected proximal to the axoneme, suggesting that the mutation does not affect the cellular localization of C2CD3 (Fig. 6K).

To determine whether the 19 bp deletion in *talpid2* *C2CD3* affected C2CD3 protein stability and size, we transfected both FLAG-C2CD3^{Ctrl} and FLAG-C2CD3^{ta2} into CEFs and performed western blot analysis. As expected, cells transfected with the FLAG-C2CD3^{ta2} produced a significantly smaller protein relative to FLAG-C2CD3^{Ctrl} (Fig. 6L), confirming that the 19 bp deletion generated a premature stop codon, producing a truncated version of C2CD3 in *talpid2* embryos. Furthermore, our western blot analysis confirms that the *talpid2* mutation does not affect C2CD3 stability or expression levels, as equal amounts of anti-FLAG staining were observed. Thus, although truncated, C2CD3 is still produced and properly localized in *talpid2* embryos.

Ciliary vesicle docking and intracellular ciliogenesis is disrupted in *talpid2* embryos

A recent study examining the role of C2CD3 in murine cells reported that the protein was localized within the transition fibers, it was required for initiating ciliogenesis via the recruitment of other centriolar distal appendage and intraflagellar transport proteins, and it was required for ciliary vesicle docking to the mother centriole (Ye et al., 2014). To determine whether the mechanism of avian C2CD3 function was similar to that of murine C2CD3, we analyzed control and *talpid2* embryos via transition electron microscopy (TEM). Specifically, we used TEM to examine intracellular




Fig. 7. Intracellular ciliogenesis is disrupted in *talpid2* embryos.

Hypothesized steps of intracellular ciliogenesis. (A) A ciliary vesicle (cv) binds to the distal end of the mother centriole (mc), via associations with transition fibers (tf). (B) Microtubule and transition zone (tz) outgrowth emerges and invaginates the cv. (C) Docking of the centriolar/cv complex to the plasma membrane. (D) Axonemal outgrowth. (A'–D') Steps of intracellular ciliogenesis in control embryos ($n=11$). (A''–D'') Intracellular ciliogenesis is significantly disrupted in *talpid2* embryos. Association of the mc with the cv and progression of the centriolar/cv complex docking with the plasma membrane rarely occur in *talpid2* embryos ($n=15$). dc, daughter centriole; pc, primary cilium; cp, ciliary pocket. Scale bars: 500 nm in A'–D''.

ciliogenesis: the process of ciliogenesis that uses transition fibers to associate with a ciliary vesicle and creates a ciliary pocket to establish an extended primary cilium (Fig. 7A–D) (Molla-Herman et al., 2010; Reiter et al., 2012). Association of the mother centriole with a ciliary vesicle was clearly detected in ~45% of control cells (Fig. 7A'). Furthermore, invagination of the ciliary vesicle associated with microtubule outgrowth from the mother centriole (Fig. 7B'), association of the mother centriole with the plasma membrane (Fig. 7C') and formation of an extended cilium within a ciliary pocket (Fig. 7D') were also frequently observed in control cells. By contrast, proper orientation and association with the ciliary vesicle was only observed in 20% of *talpid2* cells (Fig. 7A''–D''). Thus, we conclude that truncated C2CD3 in *talpid2* embryos impairs the ability of this protein to properly establish the transition fiber complex, which in turn affects intracellular ciliogenesis through failure of mother centriole/ciliary vesicle docking.

DISCUSSION

The *talpid2* is an intriguing avian mutant that has been studied by the developmental community for many years (Abbott et al., 1959; Abbott, 1967; MacCabe and Abbott, 1974). Although disruptions in SHH signaling had been implicated in this mutant, there was a lack of understanding of the cellular and molecular mechanism for this

phenotype. Furthermore, the genetic basis for this mutation was entirely unknown. We have previously suggested that defects in primary cilia exist within this mutant (Brugmann et al., 2010). Here, we confirm the aberrant structure and function of primary cilia in *talpid2* mutants and determine that SHH signaling is disrupted. Specifically, an increased amount of GLI3A in both the developing facial prominences and limb buds was observed in mutant embryos. We further identified C2CD3 as the presumptive locus containing the *talpid2* mutation via whole-genome sequencing and resequencing of multiple *talpid2* mutants. Resequencing identified a 19 bp deletion in C2CD3 that causes a premature stop codon and produces a truncated protein in *talpid2* embryos. We hypothesize that this is the casual mutation for the *talpid2* phenotype. In addition to the 19 bp deletion, however, there is a missense mutation leading to an alanine-to-proline change at codon 782 consistently found among all *talpid2* alleles (supplementary material Table S5). Although this amino acid is not widely conserved in other vertebrate C2CD3 genes, no other species contains proline at this codon. Therefore, we cannot eliminate the possibility that the Ala782Pro mutation, rather than the 19 bp deletion, leads to the mutant phenotype or, perhaps, a combination of both mutations. Reconciling the consequence(s) of this amino acid change is the focus of ongoing work.

The SHH pathway is uncoupled in a prominence-specific manner in *talpid2* mutants

Our initial work identified increased expression of SHH pathway members in *talpid2* mutants (Brugmann et al., 2010). Herein, we performed more in-depth analyses using qRT-PCR, RNA-seq and *in situ* hybridization to individually analyze each facial prominence. Often, a direct relationship between ligand and pathway activity occurs; SHH ligand expression is coupled to an increase in pathway activity, as marked by an increase in *PTC* or *GLI1* transcription. Our analysis, however, suggests that this 'coupling' of the pathway is disturbed in *talpid2* mutants in a facial prominence-specific manner. For example, there is an increase of *SHH* ligand expression in the frontonasal prominence, but *PTC* expression is reduced. By contrast, the maxillary prominence has increased *SHH* ligand expression with no change in *PTC* expression (Fig. 3). From these data, we conclude that aberrant ciliogenesis uncouples the SHH pathway in *talpid2* mutants; however, the manner in which the pathway is perturbed is dependent upon the distinct molecular environment present in the individual facial prominences.

Disruptions in GLI processing are conserved between ciliary mutants

Members of the GLI family of transcription factors have been well studied for their role in developmental processes (Hui and Angers, 2011). Defects in GLI activity have been associated with craniofacial anomalies in both humans (Greig cephalopolysyndactyly) (Vortkamp et al., 1991, 1992) and mice (Extra-toes) (Johnson, 1967). Our analysis of GLI processing during craniofacial development revealed a number of interesting findings. First, our data suggest that the *talpid2* mutation affects GLI2 differently from GLI3. GLI2 has a higher mobility in *talpid2* mutants, indicating a lack or reduction of post-translational modifications required for proper function of the protein (Fig. 4A; supplementary material Fig. S1A). GLI3, however, does not show any mobility shift or differential response to phosphatase treatment (Fig. 5A; supplementary material Fig. S1B). Thus, there could be a different cadre of proteins required for the processing of GLI2 than GLI3. Second, although examined in different tissues, the most-significant molecular defect in both *talpid2* and *talpid3* appears to be the increase in the levels of GLI3A (Fig. 5C) (Davey et al., 2006).

An increase in GLI3A suggests a net-increase in pathway activity; however, data from studies of the *talpid³* suggest that there is a gain of SHH phenotype in the limb, yet a loss of SHH phenotype in the face (Buxton et al., 2004; Davey et al., 2006, 2007). By performing tissue isolations prior to western blotting, we confirmed that GLI processing was consistent among all facial prominences and the limb in *talpid²*. Thus, using GLI protein as an indicator of pathway activity, it can be concluded that there is a gain of SHH function in both the face and limb of *talpid²*. We hypothesize that this disruption is due to reduced ciliary function in *talpid²* embryos, rather than to a direct interaction with C2CD3 protein, as neither FLAG-C2CD3^{Ctrl} nor FLAG-C2CD3^{ta2} was able to pull-down GLI3 (supplementary material Fig. S4). It will be of great interest to determine whether *TALPID3* and *C2CD3* function in parallel, or as part of a greater complex necessary for GLI processing, centriolar docking or transition fiber formation.

***talpid²* and *talpid³* are caused by distinct mutations within proteins that function in the same cellular compartment and signaling pathway**

The *talpid* mutants have long been associated with one another based simply on presentation of some similar phenotypes. Limited distribution and resources have prevented a direct comparison of the two mutations. The *talpid³* mutant has been bred and maintained in the UK, whereas the *talpid²* mutant has remained in the USA. The *talpid³* mutation has been mapped to chromosome 5 and shown to be caused by a mutation in the *KIAA0568* gene, which encodes what is now called *TALPID3* protein (Davey et al., 2006, 2007). Tickle and colleagues showed that the *KIAA0568* mutation responsible for the *talpid³* resulted in disorganized basal bodies that are unable to dock with the cell membrane and almost completely lack ciliary axonemes (Yin et al., 2009). Here, we show that the *talpid²* mutation is linked to a region on chromosome 1q within the avian ortholog of *C2CD3*. *C2CD3* was first identified via a forward genetic screen for recessive mutations affecting mouse embryonic development (Hoover et al., 2008). *hearty* and *talpid²* mutants both exhibit polydactyly, abnormal dorsal-ventral patterning and craniofacial anomalies, and both mutants have significantly increased levels of GLI3A (Abbott et al., 1959; Agarwala et al., 2005; Hoover et al., 2008). These phenotypic and molecular similarities strongly support our finding that a mutation in *C2CD3* is causal for the *talpid²* phenotype.

Although the exact function of *C2CD3* is currently unknown, recent studies suggest *C2CD3* is localized to the distal ends of both mother and daughter centrioles, and is required for the recruitment of centriolar distal appendage proteins (Jakobsen et al., 2011; Balestra et al., 2013; Ye et al., 2014). *In vitro* analysis further suggests that *C2CD3* is required for recruiting the intraflagellar transport proteins IFT88 and IFT52 to the mother centriole, and is essential for ciliary vesicle docking to the mother centriole (Ye et al., 2014). Thus, our data, together with that of others, suggest that the *C2CD3* protein regulates intracellular ciliogenesis by promoting the assembly of centriolar distal appendages that are crucial for docking ciliary vesicles and anchoring the centriolar complex to the cell membrane. This is an intriguing hypothesis, as the *TALPID3* protein also reportedly functions to anchor the centriole to the membrane (Yin et al., 2009), perhaps via functioning within the transition fibers.

Future studies are needed to elucidate the exact role of *C2CD3*, primary cilia and GLI trafficking/processing in craniofacial development. The identification of avian *C2CD3* opens the possibility that *talpid²* may be a relevant model for human disease. Both the *talpid²* and *talpid³* mutations have provided new insights

into craniofacial ciliopathies, which can be used to elucidate the pathways and regulatory mechanisms behind ciliopathic diseases. Interestingly, a number of human craniofacial ciliopathies are caused by mutations in proteins that localize to the distal centriole or proximal axoneme, including Meckel syndrome, Joubert syndrome, nephronophthisis and Senior-Loken syndrome (Reiter et al., 2012). The *C2CD3* ortholog in humans is in the HSA11q13.4 chromosomal region, in close proximity to the critical regions for other human ciliopathies, including Meckel-Gruber syndrome 2 (MKS; 603194), Joubert syndrome 2 (JBTS2; 608091) and Nephronophthisis 15 (NPHP15; 614845) (Roume et al., 1998; Hoover et al., 2008; Valente et al., 2010). Thus, the continued examination of the role of *C2CD3* has direct relevance for the study of human diseases.

MATERIALS AND METHODS

Embryo preparation and measurement of facial prominences

talpid² heterozygous carriers were mated and eggs were collected. Embryos were incubated at 37°C for 2–7 days. Facial measurements were performed using Leica software. FNP length was defined as the superior aspect of the nasal pit to the distal tip of the FNP. FNP width was defined as the widest aspect of the distal FNP. Infranasal distance was the distance between the medial aspects of the nasal pits. Palatal patency was defined as the length of patency of the palatal shelves. *P*-values were determined using Student's two-tailed *t*-test with variance being unequal.

Scanning and transmission electron microscopy

Facial and forebrain tissue were collected from control and *talpid²* HH20 embryos. Samples were fixed in 0.1 M sodium cacodylate (pH 7.4) containing 4% paraformaldehyde and 2% glutaraldehyde, re-fixed in 1% osmium tetroxide, dehydrated in ethanol, dried, mounted and sputter-coated with 20 nm of gold. Images were collected at 2.0 keV in a Zeiss Supra-35VP FEG.

For transmission electron microscopy, tissue was fixed with 3% glutaraldehyde, washed with sodium cacodylate buffer, post-fixed with 1% OsO₄, processed through an ethanol gradient, washed in serial dilutions of plastic (Ladd Research, LX-112)/propylene oxide mixture and moved to 60°C for 3 days. The tissue was sectioned by Leica EM UC7 ultramicrotome at 100 nm and put onto 200 mesh copper grids.

Chicken embryonic fibroblast isolation and transfection

Facial prominences and limbs were collected from HH25 control or mutant embryos, and were digested with 1 mg/ml collagenase at 37°C for 30 min. Cells were dissociated, washed in PBS and plated in DMEM with 10% fetal bovine serum and 50 U/ml penicillin-streptomycin. Chick embryonic fibroblasts (CEFs) were plated at 70% confluency and transfection was carried out using X-tremeGENE HP DNA transfection reagent (Roche) according to the manufacturer's protocol.

Quantitative RT-PCR, RT-PCR and RNA-seq

Facial prominences were collected and pooled from ~10 control or mutant embryos. RNA was extracted using TRIzol reagent (Invitrogen) and cDNA was made using SuperScript III (Invitrogen). SsoAdvanced SYBR Green Supermix (Bio-Rad) and a CFX96 Touch real-time PCR detection system (Bio-Rad) were used to perform quantitative real-time PCR. All the genes were normalized to GAPDH expression. Student's *t*-test was used for statistical analysis. *P*<0.05 was determined to be significant. Primers included: GAPDH F, CAACATCAAATGGGCAGATG; GAPDH R, AGCTGAGGGAGCT-GAGATGA; C2CD3 F, GAGGAAAGCAGTGAGGTTCTA AA; C2CD3 R, CTCCAGGATGGCAATTTCG (amplicon size 782 bp).

For RNA-seq, individual facial prominences were harvested from control (*n*=8) and *talpid²* (*n*=8) embryos at HH25. RNAs were processed according to recommended procedures, using the Illumina TruSeq and Nugen Ovation RNA-Seq System V2 methods. Sequencing was carried out using the Illumina HiSeq 2000 system according to Illumina protocols. BAM files underwent whole-genome RNA-seq analysis using GeneSpring Version 12.5-GX-NGS. The reference chick genome was taken from Ensembl (4/9/2012). The Audic

Claverie test (no correction) was used to identify differentially expressed genes between control and *talpid²* facial prominences with a $P \leq 0.05$. Heatmaps were generated by GeneSpring after performing the Pathway Analysis function. Raw data have been deposited in GEO under accession number GSE52757.

In situ hybridization

In situ hybridization was performed using digoxigenin-labeled riboprobes, as described on the Gallus Expression *in situ* hybridization Analysis site (GEISHA) (Bell et al., 2004; Darnell et al., 2007).

Immunohistochemistry

Immunostaining was performed according to standard protocols. Briefly, embryos were fixed in either 100% methanol or DENTS fixative. CEFs were fixed in 4% PFA. Samples were blocked with 10% serum (Millipore) for 30 min at room temperature and incubated with primary antibody at 4°C overnight and with Alexa Fluor 594Ms or 488Rb secondary antibodies (1:1000; A11020 or A11070; Invitrogen) for 1 h. Slides were stained with 4',6-diamino-2-phenylindole (DAPI; 5 µg/ml; Invitrogen) and mounted (ProLong Gold, Invitrogen). Antibodies included rabbit anti-glutamylated-tubulin (1:500; AB3201, Millipore), mouse anti-γ-tubulin (1:1000; T6557, Sigma) and anti-FLAG (1:1000; F1804, Sigma). The percentage of primary cilium extension in CEFs was measured in at least 20 microscopic fields. The *P*-value was determined using Student's *t*-test.

Western blot analysis

Facial prominences and limbs were dissected from HH25 control or *talpid²* embryos. Tissue was rinsed with ice-cold NaCl and sonicated in RIPA buffer containing protease and phosphatase inhibitors (Thermo Scientific, #87786). Protein concentration was measured by BCA protein assay (Thermo Scientific, #23227) and 30 µg protein was applied to a 6% SDS-PAGE gel. Antibodies used included anti-Gli2 antibody (1:500; R&D, AF3635), anti-Gli3 antibody (1:1000; R&D, AF3690) and anti-β-actin antibody (1:10,000; Abcam, ab8227).

Nuclear fractionation

Facial prominences and developing limbs were dissected from HH 25 chicken embryos. Tissue was rinsed with PBS and digested with 2 mg/ml collagenase (Sigma, C2674). Nuclear fractionation was performed using NE-PER Nuclear and Cytoplasmic Extraction Reagents (Pierce, #78833).

Phosphatase treatment

Total proteins (100 µg) from control facial prominences were collected and treated with phosphatase (New England Biolabs, P0753S) at 30°C for 1 h. Laemmli buffer was added and the sample was boiled at 95°C for 5 min before performing western blot analyses.

Morpholino transfection

Control CEFs were grown to 80% confluency, trypsinized and resuspended in DMEM at a concentration of 1×10^7 /ml. Cells (3×10^6 in 300 µl) were mixed with either 3 µl of 1 mM control-MO or with two separate C2CD3 translational MOs (C2CD3-MO1, 5'-CTGCATGGCTTCACCTCAAC-GCTT-3'; C2CD3-MO2, 5'-AACAGCCGCCCGACGGGAGCATCT-3') to a final concentration of 10 µM. Electroporation was performed using a geneZAPPER 450/2500 system at 950 µF and 200 V. After electroporation, 30 µl of the cells/well were plated on fibronectin-coated (5 µg/cm²) cover slips. Cells were serum starved for 48 h and immunostained. The percentage of ciliary extension in CEFs was measured in at least 20 microscopic fields. *P*-values were determined using Student's *t*-test.

Genetic lines, sequencing and analysis

Embryonic samples used for this study were from four genetic lines: the developmental mutant-congenic inbred line *talpid2.003* (also known as *ta2.003*) and its inbred ($F > 0.99$) parent background line UCD003, as well as the *talpid²* mutation integrated onto a commercial white leghorn line (CWLL) and the outbred parental genetic background CWLL. The DNA from 10 known *talpid2.003* mutants (−/−) and six inbred UCD 003 individuals were

isolated and prepared for whole-genome sequencing. Samples were sequenced via NGS by DNA Landmarks (Saint-Jean-sur-Richelieu, Quebec, Canada) on the Illumina Hi-Seq platform. Reads were mapped to the reference chicken genome and polymorphisms (single nucleotide polymorphisms, SNPs, small insertion/deletions and structural rearrangements) were called using the CLC Genomics Workbench (CLC bio).

Acknowledgements

We thank the UC Davis Avian Facility and Jackie Piseni for husbandry of the *talpid²* line. We also acknowledge and thank Jaime Struve for technical support and careful reading of the manuscript, Dr Rashmi Hegde for sequence analysis and protein modeling, Dr Matt Kofron for assistance with microscopy, Georgianne Ciruolo and the CCHMC Pathology core for assistance with TEM, and faculty members of the Division of Developmental Biology at CCHMC for critical discussion of the research project.

Competing interests

The authors declare no competing financial interests.

Author contributions

C.-F.C. performed and interpreted most experiments, including immunofluorescence, western blotting, nuclear fractionation, cloning, subcloning, immunoprecipitation, transfection and qRT-PCR. E.N.S. performed facial prominence measurements, *in situ* hybridization and PCR, and analyzed RNA-seq results. E.A.O., J.D., H.H.C., W.M.M. and M.E.D. performed and analyzed all sequencing data. R.E.E. performed scanning electron microscopy. M.E.D. supplied *talpid²* eggs. S.A.B. conceived the project, interpreted experiments and wrote the manuscript with input from all authors.

Funding

This work was funded by the National Institutes of Health, National Institute of Dental and Craniofacial Research (NIDCR) [R00-DE01985 to S.A.B.], by C.T.O. funds from the Cincinnati Children's Research Foundation to S.A.B., by the John and Joan Fiddymend Endowment (University of California, Davis) to M.E.D., and by the NRSP-8 National Animal Genome Research Support Program [CA-D*-ASC-7233-RR to M.E.D.]. Deposited in PMC for immediate release.

Supplementary material

Supplementary material available online at <http://dev.biologists.org/lookup/suppl/doi:10.1242/dev.105924/-/DC1>

References

- Abbott, U. K. (1967). Avian developmental genetics. In *Methods in Developmental Biology* (ed. F. H. Wilt and N. K. Wessels), pp. 13–52. New York: Thomas Y. Crowell Company.
- Abbott, U. K., Taylor, L. W. and Abplanalp, H. (1959). A second *talpid*-like mutation in the fowl. *Poult. Sci.* **38**, 1185.
- Abbott, U. K., Taylor, L. W. and Abplanalp, H. (1960). Studies with *talpid²*, an embryonic lethal of the fowl. *J. Hered.* **51**, 195–202.
- Agarwala, S., Aglyamova, G. V., Marma, A. K., Fallon, J. F. and Ragsdale, C. W. (2005). Differential susceptibility of midbrain and spinal cord patterning to floor plate defects in the *talpid2* mutant. *Dev. Biol.* **288**, 206–220.
- Bai, C. B., Auerbach, W., Lee, J. S., Stephen, D. and Joyner, A. L. (2002). Gli2, but not Gli1, is required for initial Shh signaling and ectopic activation of the Shh pathway. *Development* **129**, 4753–4761.
- Balestra, F. R., Strnad, P., Flückiger, I. and Gönczy, P. (2013). Discovering regulators of centriole biogenesis through siRNA-based functional genomics in human cells. *Dev. Cell* **25**, 555–571.
- Bell, G. W., Yatskievych, T. A. and Antin, P. B. (2004). GEISHA, a whole-mount *in situ* hybridization gene expression screen in chicken embryos. *Dev. Dyn.* **229**, 677–687.
- Biesecker, L. G. (1997). Strike three for GLI3. *Nat. Genet.* **17**, 259–260.
- Brugmann, S. A., Allen, N. C., James, A. W., Mekonnen, Z., Madan, E. and Helms, J. A. (2010). A primary cilia-dependent etiology for midline facial disorders. *Hum. Mol. Genet.* **19**, 1577–1592.
- Buxton, P., Davey, M. G., Paton, I. R., Morrice, D. R., Francis-West, P. H., Burt, D. W. and Tickle, C. (2004). Craniofacial development in the *talpid3* chicken mutant. *Differentiation* **72**, 348–362.
- Canettieri, G., Di Marcotullio, L., Greco, A., Coni, S., Antonucci, L., Infante, P., Pietrosanti, L., De Smaele, E., Ferretti, E., Miele, E. et al. (2010). Histone deacetylase and Cullin3-REN(KCTD11) ubiquitin ligase interplay regulates Hedgehog signalling through Gli acetylation. *Nat. Cell Biol.* **12**, 132–142.
- Caruccio, N. C., Martinez-Lopez, A., Harris, M., Dvorak, L., Bitgood, J., Simandl, B. K. and Fallon, J. F. (1999). Constitutive activation of sonic hedgehog signaling

- in the chicken mutant talpid2: Shh-independent outgrowth and polarizing activity. *Dev. Biol.* **212**, 137-149.
- Chong, H. J., Young, N. M., Hu, D., Jeong, J., McMahon, A. P., Hallgrimsson, B. and Marcucio, R. S. (2012). Signaling by SHH rescues facial defects following blockade in the brain. *Dev. Dyn.* **241**, 247-256.
- Cox, B., Briscoe, J. and Ulloa, F. (2010). SUMOylation by Pias1 regulates the activity of the Hedgehog dependent Gli transcription factors. *PLoS ONE* **5**, e11996.
- Darnell, D. K., Kaur, S., Stanislaw, S., Davey, S., Konieczka, J. H., Yatskevich, T. A. and Antin, P. B. (2007). GEISHA: an in situ hybridization gene expression resource for the chicken embryo. *Cytogenet. Genome Res.* **117**, 30-35.
- Davey, M. G., Paton, I. R., Yin, Y., Schmidt, M., Bangs, F. K., Morrice, D. R., Smith, T. G., Buxton, P., Stamatakis, D., Tanaka, M. et al. (2006). The chicken talpid3 gene encodes a novel protein essential for Hedgehog signaling. *Genes Dev.* **20**, 1365-1377.
- Davey, M. G., James, J., Paton, I. R., Burt, D. W. and Tickle, C. (2007). Analysis of talpid3 and wild-type chicken embryos reveals roles for Hedgehog signalling in development of the limb bud vasculature. *Dev. Biol.* **301**, 155-165.
- Ding, Q., Motoyama, J., Gasca, S., Mo, R., Sasaki, H., Rossant, J. and Hui, C. C. (1998). Diminished Sonic hedgehog signaling and lack of floor plate differentiation in Gli2 mutant mice. *Development* **125**, 2533-2543.
- Ede, D. A. and Kelly, W. A. (1964a). Developmental abnormalities in the head region of the talpid mutant of the fowl. *J. Embryol. Exp. Morphol.* **12**, 161-182.
- Ede, D. A. and Kelly, W. A. (1964b). Developmental abnormalities in the trunk and limbs of the talpid3 mutant of the fowl. *J. Embryol. Exp. Morphol.* **12**, 339-356.
- Goetz, S. C. and Anderson, K. V. (2010). The primary cilium: a signalling centre during vertebrate development. *Nat. Rev. Genet.* **11**, 331-344.
- Hamburger, V. and Hamilton, H. L. (1951). A series of normal stages in the development of the chick embryo. *J. Morphol.* **88**, 49-92.
- Haycraft, C. J., Banizs, B., Aydin-Son, Y., Zhang, Q., Michaud, E. J. and Yoder, B. K. (2005). Gli2 and Gli3 localize to cilia and require the intraflagellar transport protein polaris for processing and function. *PLoS Genet.* **1**, e53.
- Hinchliffe, J. R. and Ede, D. A. (1968). Abnormalities in bone and cartilage development in the talpid mutant of the fowl. *J. Embryol. Exp. Morphol.* **19**, 327-339.
- Hoover, A. N., Wynkoop, A., Zeng, H., Jia, J., Niswander, L. A. and Liu, A. (2008). C2cd3 is required for cilia formation and Hedgehog signaling in mouse. *Development* **135**, 4049-4058.
- Huangfu, D. and Anderson, K. V. (2005). Cilia and Hedgehog responsiveness in the mouse. *Proc. Natl. Acad. Sci. USA* **102**, 11325-11330.
- Hui, C.-C. and Angers, S. (2011). Gli proteins in development and disease. *Annu. Rev. Cell Dev. Biol.* **27**, 513-537.
- Hui, C.-C. and Joyner, A. L. (1993). A mouse model of greig cephalopolysyndactyly syndrome: the extra-toesJ mutation contains an intragenic deletion of the Gli3 gene. *Nat. Genet.* **3**, 241-246.
- Humke, E. W., Dorn, K. V., Milenkovic, L., Scott, M. P. and Rohatgi, R. (2010). The output of Hedgehog signaling is controlled by the dynamic association between Suppressor of Fused and the Gli proteins. *Genes Dev.* **24**, 670-682.
- Jakobsen, L., Vanselow, K., Skogs, M., Toyoda, Y., Lundberg, E., Poser, I., Falkenby, L. G., Bennetzen, M., Westendorf, J., Nigg, E. A. et al. (2011). Novel asymmetrically localizing components of human centrosomes identified by complementary proteomics methods. *EMBO J.* **30**, 1520-1535.
- Johnson, D. R. (1967). Extra-toes: a new mutant gene causing multiple abnormalities in the mouse. *J. Embryol. Exp. Morphol.* **17**, 543-581.
- Lillie, F. R. (1908). *The Development of the Chick: an Introduction to Embryology*. New York: Henry Holt and Company.
- Liu, A., Wang, B. and Niswander, L. A. (2005). Mouse intraflagellar transport proteins regulate both the activator and repressor functions of Gli transcription factors. *Development* **132**, 3103-3111.
- MacCabe, J. A. and Abbott, U. K. (1974). Polarizing and maintenance activities in two polydactylous mutants of the fowl: diplopodia and talpid. *J. Embryol. Exp. Morphol.* **31**, 735-746.
- Marcucio, R. S., Cordero, D. R., Hu, D. and Helms, J. A. (2005). Molecular interactions coordinating the development of the forebrain and face. *Dev. Biol.* **284**, 48-61.
- May, S. R., Ashique, A. M., Karlen, M., Wang, B., Shen, Y., Zarbalis, K., Reiter, J., Ericson, J. and Peterson, A. S. (2005). Loss of the retrograde motor for IFT disrupts localization of Smo to cilia and prevents the expression of both activator and repressor functions of Gli. *Dev. Biol.* **287**, 378-389.
- Molla-Herman, A., Ghossoub, R., Blisnick, T., Meunier, A., Serres, C., Silbermann, F., Emmerson, C., Romeo, K., Bourdoncle, P., Schmitt, A. et al. (2010). The ciliary pocket: an endocytic membrane domain at the base of primary and motile cilia. *J. Cell Sci.* **123**, 1785-1795.
- Motoyama, J., Liu, J., Mo, R., Ding, Q., Post, M. and Hui, C.-C. (1998). Essential function of Gli2 and Gli3 in the formation of lung, trachea and oesophagus. *Nat. Genet.* **20**, 54-57.
- Pan, Y., Bai, C. B., Joyner, A. L. and Wang, B. (2006). Sonic hedgehog signaling regulates Gli2 transcriptional activity by suppressing its processing and degradation. *Mol. Cell. Biol.* **26**, 3365-3377.
- Pan, Y., Wang, C. and Wang, B. (2009). Phosphorylation of Gli2 by protein kinase A is required for Gli2 processing and degradation and the Sonic Hedgehog-regulated mouse development. *Dev. Biol.* **326**, 177-189.
- Park, H. L., Bai, C., Platt, K. A., Matise, M. P., Beeghly, A., Hui, C. C., Nakashima, M. and Joyner, A. L. (2000). Mouse Gli1 mutants are viable but have defects in SHH signaling in combination with a Gli2 mutation. *Development* **127**, 1593-1605.
- Persson, M., Stamatakis, D., te Welscher, P., Andersson, E., Böse, J., Rütger, U., Ericson, J. and Briscoe, J. (2002). Dorsal-ventral patterning of the spinal cord requires Gli3 transcriptional repressor activity. *Genes Dev.* **16**, 2865-2878.
- Reiter, J. F., Blacque, O. E. and Leroux, M. R. (2012). The base of the cilium: roles for transition fibres and the transition zone in ciliary formation, maintenance and compartmentalization. *EMBO Rep.* **13**, 608-618.
- Robb, E. A., Gitter, C. L., Cheng, H. H. and Delany, M. E. (2011). Chromosomal mapping and candidate gene discovery of chicken developmental mutants and genome-wide variation analysis of MHC congenics. *J. Hered.* **102**, 141-156.
- Roume, J., Genin, E., Cormier-Daire, V., Ma, H. W., Mehaye, B., Attie, T., Razavi-Encha, F., Fallet-Bianco, C., Buenerd, A., Clerget-Darpoux, F. et al. (1998). A gene for Meckel syndrome maps to chromosome 11q13. *Am. J. Hum. Genet.* **63**, 1095-1101.
- Schneider, R. A., Hu, D. and Helms, J. A. (1999). From head to toe: conservation of molecular signals regulating limb and craniofacial morphogenesis. *Cell Tissue Res.* **296**, 103-109.
- Valente, E. M., Logan, C. V., Mougou-Zerelli, S., Lee, J. H., Silhavy, J. L., Brancati, F., Iannicelli, M., Travaglini, L., Romani, S., Illi, B. et al. (2010). Mutations in TMEM216 perturb ciliogenesis and cause Joubert, Meckel and related syndromes. *Nat. Genet.* **42**, 619-625.
- Vortkamp, A., Gessler, M. and Grzeschik, K.-H. (1991). Gli3 zinc-finger gene interrupted by translocations in Greig syndrome families. *Nature* **352**, 539-540.
- Vortkamp, A., Franz, T., Gessler, M. and Grzeschik, K. H. (1992). Deletion of Gli3 supports the homology of the human Greig cephalopolysyndactyly syndrome (GCPS) and the mouse mutant extra toes (Xt). *Mamm. Genome* **3**, 461-463.
- Wen, X., Lai, C. K., Evangelista, M., Hongo, J.-A., de Sauvage, F. J. and Scales, S. J. (2010). Kinetics of hedgehog-dependent full-length Gli3 accumulation in primary cilia and subsequent degradation. *Mol. Cell. Biol.* **30**, 1910-1922.
- Ye, X., Zeng, H., Ning, G., Reiter, J. F. and Liu, A. (2014). C2cd3 is critical for centriolar distal appendage assembly and ciliary vesicle docking in mammals. *Proc. Natl. Acad. Sci. USA* **111**, 2164-2169.
- Yee, G. W. and Abbott, U. K. (1978). Facial development in normal and mutant chick embryos. I. Scanning electron microscopy of primary palate formation. *J. Exp. Zool.* **206**, 307-321.
- Yin, Y., Bangs, F., Paton, I. R., Prescott, A., James, J., Davey, M. G., Whitley, P., Genikhovich, G., Technau, U., Burt, D. W. et al. (2009). The Talpid3 gene (KIAA0586) encodes a centrosomal protein that is essential for primary cilia formation. *Development* **136**, 655-664.
- Young, N. M., Chong, H. J., Hu, D., Hallgrimsson, B. and Marcucio, R. S. (2010). Quantitative analyses link modulation of sonic hedgehog signaling to continuous variation in facial growth and shape. *Development* **137**, 3405-3409.
- Zhang, D. and Aravind, L. (2012). Novel transglutaminase-like peptidase and C2 domains elucidate the structure, biogenesis and evolution of the ciliary compartment. *Cell Cycle* **11**, 3861-3875.




Figure S1. Phosphatase treatment of GLI2 and GLI3. (A) Phosphatase treatment of control full-length GLI2-185 did not shift mobility to that of the *talpid*² GLI2-185. (B) Phosphatase treatment shifted GLI3-190 in both control and *talpid*² embryos.

```

GTGAAGCGGGAGATGCTCCCGTCGGGGCGGCTGTTGCCGGGCAGCGGCGCGCCTGAGG
GAAGCGTTGAGGTGAAGCC
1 ATGCAGCAGAGGAGGCCGCGGGCCTCAGCCCCAGCCCCGGGGTCCAGCCGGCGGCTCGA 60
M Q Q R R P R A S A P A P G V S R R R R 20

Exon2
61 GCTCCCGTGACATCCCGGCTCCACCAGCCTGCCGCGCTGGTGGAGGGCCCTCCGCGC 120
A P G D I P A S T S L P P L V E G P P R 40

121 TCGTCTCTGCTGCACCGTGGGCAGAATCGTGTGGACGGCCGCAAAACCGCCTCCGCC 180
C V L C C T V G R I V W T A A K P P S A 60

181 GCCGTCTCTGTCGCGCTGAGGTGGTGGGGTGAGACCTCGGACGGTACCGTGTTCACCCC 240
A V L V R L R W W G E T S D G T V F H P 80

241 TCCTCAAAGCCGGGCGAGGCGGGCGGCGAGCCGGTACACCGTGCGGTGCGGGCGCTCGG 300
S S K P G Q A A G S S R Y T V R C G P R 100

Exon3
301 CAGCTCACGGCCTACCTCAGAGTATGGGCATGCTTGTCTGGAGGTCTGACAAACCT 360
Q L T A Y L T D M G M L V L E V L T K P 120

361 GACCGTCTTCCAGTTGGCAGAGTGCAGATCACCGAATTGTCCAGCTCTCTCCAGCCAT 420
D R L P V G R V Q I T E L S Q L S P S H 140

Exon4
421 CCCATCAGTGGGTTTTCACCATAGTTTACCAACAGCTGATAAACTGGGAGAGCTACAG 480
P I S G F F T I V S P T A D K L G E L Q 160

481 GTTCACTTGTCTCGAACCTCTATCAGACACATACAAAACAGCAGCTCTGTCCCAACC 540
V S L V L E P L S D T Y K T S S S V P T 180

541 ACAGCTACAAGTTCAGATATGACTCCTGCTCCATCGCAGCAAATGCAGACCCTCCTCCT 600
T A T S S D M T P A P S Q Q M Q T T P P 200

Exon5
601 GGCCAAGAGCCTGTAAACAAAAGCAGGGTCACGACTCCCACTGGGGAAAGGACCATTCA 660
G Q E P V N K S R V T T P S W G K D H S 220

661 TTCTTTCAAGAGAACTCTGAAAACATAAAGGATGTTTCTCTGCTTCCCACCACCGCTC 720
F F Q E N S E N I K D V S S A S H H R L 240

721 ATTTTACCAGATGAACATTTGAAAGTGAATCCTTTGAGTCAGCAGTCAGTATCATTCCCC 780
I L P D E H L K V N P L S Q Q S V S F P 260

781 AGCAGCACTGATCCTGAAGCACCCCTCAGTACAAACACACCGTGTTCCTTGCACAAC 840
S S T D P E A P L S T N T H V F S L H N 280

Exon6
841 CCAACTACAAAAGACCTGCTTTCAGCTCTTTTGGATCAAGGCAATAAACTCCGTGATGCC 900
P T T K D L L S A L L D Q G N K L R D A 300

901 ATGGTTGCTTCTGCAATGAAGTCCAGCCCAGACATGGAGATTGAATTGAATGAAGTGCCT 960
M V A S A M K S S P D M E I E L N E V P 320

Exon7
961 CCTTTTGTAAAGCCAGATGGTTTCAGAGCAGCAGCAAGAGCCCAAAGGCTTGAATCA 1020
P F V K P D G F R A A A K S P K G L N S 340

1021 ACTTTTATGCCTCCTCCTGAGGATACCCATCTCTTACATCTGAAGTCACAGGTACAGCAA 1080
T F M P P P E D T H L F T S E V T G Q Q 360

Exon8
1081 TTAGACCTCAACTCTGAGGAGAGAGCAATACAGTTACTGTTGGGCAGTGTGATTATCT 1140
L D L N S E E R A I Q L L L G S A D L S 380

1141 CCTGTGCATTTCTGGGATCAGCCAGGTTCCCTTCTGGATTCTCTCTGTTGGAAGTGAG 1200
P V H F W D Q P G S L L D S L S V G S E 400

1201 GTGTATGACAGTGAACCTAATGATCCCCACTATGACCAGAGTCTGCTAGAAAGCTTTTT 1260
V Y D S E L N D P H Y D Q S L L E S L F 420

Exon9
1261 TACACGACACCTAAATCAGATTCCAGTACAAGTGATTTCCTCAGTGATGAAGATGTTAAC 1320
Y T T P K S D S S T S D F L S D E D V N 440

1321 CCTTCAAAAAAGTAAGCAAAACAAAACGTGAAGAAAGCTGATTCTGTGAATGCACAG 1380
P S K K V S K T K T V K K A D S V N A Q 460

Exon10
1381 AAGGATTCCACTGCCTTAGATCAGGATCAGAAGGTGACAGAAATTAACCCAGTGTCTCT 1440

```

Figure S2. cDNA and amino acid sequence of chicken C2CD3.




Figure S3. *C2CD3* is expressed in whole chicken embryos. (A-B') *In situ* hybridization for *C2CD3* in day 4 whole embryos. Scale bar represents 500 μ m.




Figure S4. *C2CD3* does not interact with *GLI3*. CEFs were transfected with either p3XFLAG-*c2cd3*^{Ctrl} or p3XFLAG-*c2cd3*^{ta2} and immunoprecipitation was performed with anti-GLI3. * indicates GLI3-190, > indicates cleaved GLI3-83.

Table S1. Densitometry readings of GLI2 and GLI3 nuclear fraction

GLI2				GLI3				LAMIN			
		raw #	normalized		raw#	normalized		raw #	normalized		
FNP	ctrl	1926.882	1		3982.368	1		2948.882	1		
	TA2	2688.489	1.395253575		16254.154	4.081529884		4076.276	1.382312348		
MXP	ctrl	4366.518	1		6927.711	1		3294.225	1		
	TA2	4703.43	1.077158047		19972.267	2.882953258		3812.296	1.157266428		
MNP	ctrl	2385.305	1		3486.794	1		4547.205	1		
	TA2	4756.903	1.994253565		12053.296	3.456842016		9019.539	1.983534721		

Table S2.

[Download Table S2](#)

Table S3.

[Download Table S3](#)

Table S4. Variant frequency in ta2.003 candidate intervals

candidate ta-2 region	size	UCD003	UCD003	tal2-specific	tal2-specific	UCD003	tal2-specific	fixed tal2-specific	fixed tal2-specific	fixed ta-2/UCD003	tal2/UCD003
Galg4 coordinates	Mb	SNP	DIP	SNP	DIP	SNP/Mb	SNP/Mb	SNP	SNP/Mb	SNP ratio	DIP ratio
chr1:115764249-118327843	2.56	25484	1407	2575	335	9955	1006	752	294	0.030	0.24
chr1:193748573-195187547	1.44	15300	658	2819	238	10625	1958	1550	1076	0.101	0.36
chr10:8513002-10170824	1.66	14620	815	1134	151	8807	683	314	189	0.021	0.19
chr10:11552743-12453463	0.90	11022	627	730	95	12247	811	89	99	0.008	0.15
chr15:10301074-11866661	1.57	17508	857	125	40	11152	80	59	38	0.003	0.05

Variant frequencies are shown (total and per Mb) for UCD003 and ta2.003-specific. Fixed refers to those variants found in all ta2.003 reads that likely include fewer false positives. DIP, deletion/insertion polymorphism.

Table S5. Coding variants in C2CD3

mRNA coord rel to ATG 89	Coordinate (Galgal4)	Reference C	GGA1 Reference		variant in ta2.003
			ta2.003 G	Amino Acid Change Ser30Thr	
167	194883741	T	C	Lys56Arg	ta2.003
957	194879146	C	T	synonymous	ta2.003
2178	194867809	G	A	synonymous	ta2.003
2325	194867662	G	A	synonymous	ta2.003
2344	194867643	C	G	Ala782Pro	ta2.003
2346	194867641	A	G	synonymous	ta2.003
4049	194858002	C	T	Gly1350Asp	ta2.003
4595	194856869	G	A	Pro1532Leu	ta2.003
4598	194856866	G	A	Thr1533Ile	ta2.003
4674	194856790	C	A	Gln1558His	ta2.003
5870	194844961	C	T	Gly1957Asp	ta2.003
6570	194844261	T	C	synonymous	ta2.003
6626-6644	194844184-194844202		19 bp deletion	deletes a.a. from 2210-2330	ta2.003
				synonymous after	
6648	194844180	A	G	frameshift/stop	ta2.003
6767	194842820	A	G	Val2256Ala after frameshift/stop	ta2.003
1022	194877027	G	T	Thr341Asn	ta2.003 and UCD003
1194	194875767	T	C	synonymous	ta2.003 and UCD003

Exonic variants confirmed by whole genome sequencing and resequencing in C2CD3.